Polycystic ovarian syndrome (PCOS) is a hormonal disorder and is the main cause of infertility in women. The most known risk factors are obesity and insulin resistance which are usually found in children with growth hormone deficiency (GHD). PCOS begins with altered pulsatile GnRH release, leading to increase production of luteinizing hormone (LH). The excessive accumulation of LH stimulates the production of androgens in the ovaries. The increase of androgens (especially androstenedione) plays a role in the patient's abnormal lipid profile, hirsutism and acne. Children with Growth Hormone Deficiency (GHD) have a low lipid profile that can lead to obesity and insulin resistance. These are known as risk factors for PCOS. The recommended starting dose of GH is 0.025 mg/kg/day and the dose is then adjusted to 0.05 mg/kg/day. Studies found positive effects of the therapy for child growth and metabolism. So that the provision of GH therapy in children is expected to improve the quality of life by improving growth and preventing PCOS in the future. GH therapy in children with GHD can help in achieving optimal height and preventing the risk of PCOS from an early age.